The Effect of "Stellate Ganglion Block" on Inflammatory Response in Acute Pancreatitis

The Effect of stellate ganglion block on inflammatory response in acute pancreatitis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077203

Enrollment

Unknown

Registered

2023-11-01

Start date

2023-11-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Experimental group:Standard treatment+ Stellate ganglion block

Control Group:Standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Diagnosed with acute pancreatitis and admitted to hospital within 7 days of onset; ? Aged between 18 and 70 years old.

Exclusion criteria

Exclusion criteria: ? Pancreatitis during pregnancy; ? Severe pancreatitis, chronic pancreatitis or pancreatitis related to pancreatic tumors; ? Those who have undergone surgical drainage and debridement, and those who need emergency ERCP treatment; ? Those who have undergone cardiopulmonary resuscitation before and whose neurological function has not recovered; ? Patients with a history of severe cardiovascular, respiratory, renal, liver, hematological, malignant tumors or immune diseases: (1) heart failure greater than NYHA cardiac function class II; (2) active myocardial ischemia; (3) in Cardiovascular intervention within 60 days; (4) history of liver cirrhosis; (5) chronic kidney disease, creatinine clearance <40 mL/min; (6) chronic obstructive pulmonary disease requiring home oxygen therapy; ?Those who are allergic to local anesthetics; ? Those with a history of neck surgery, scars, anatomical variations, and inability to perform "stellate ganglion block"; ? Those who have coagulation disorders or are undergoing anticoagulation treatment.

Design outcomes

Primary

Measure	Time frame
IL-6;	—

Secondary

Measure	Time frame
Blood inflammation markers;Vital signs;The incidence, time, and location of abdominal bleeding;The incidence, time, and location of gastrointestinal perforation or fistula;Sleep quality and delirium scores;Mortality rate;Severe pancreatitis conversion rate;Total cost of treatment and ICU treatment time;The incidence and timing of sepsis;The incidence and frequency of surgical procedures;The situation of systemic inflammatory response syndrome after inclusion;Organ dysfunction after inclusion;	—

Measure

Time frame

Blood inflammation markers;Vital signs;The incidence, time, and location of abdominal bleeding;The incidence, time, and location of gastrointestinal perforation or fistula;Sleep quality and delirium scores;Mortality rate;Severe pancreatitis conversion rate;Total cost of treatment and ICU treatment time;The incidence and timing of sepsis;The incidence and frequency of surgical procedures;The situation of systemic inflammatory response syndrome after inclusion;Organ dysfunction after inclusion;

—

Countries

China

Contacts

Public ContactHong Yu

Sir Run Run Shaw Hospital, Medical School, Zhejiang University

blueyu000@zju.edu.cn+86 136 0570 5907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026